A 5-Day Losing Streak Has ImmunityBio Stock Down 30%

• IBRX fell 30.3% over five days, wiping out $2.8B in value • Revenue grew 121% YoY but operating margin stands at -150% • The drop was company-specific as the S&P 500 rose 2.5% over the same period IBRX plunged 30.3% in five days, erasing $2.8 billion in market value. The stock now trades at $6.02, 47.9% below its 52-week high. Revenue jumped 121% over the trailing twelve months, far ahead of the S&P 500 Health Care median of 7.9%, yet the operating margin is -150.2% versus the sector median of 17.4%. The S&P 500 rose 2.5% over the same five-day window, confirming the slide was company-specific. For diversified investors, this weakness is noise; for concentrated holders, it underscores the need for a resilient portfolio.